A Retrospective Study in Patients With Liver Injury After the Use of Novel Antineoplastic Agents

NCT06670391 · tracked via the Priya Life Science China tracker

Sponsor

Drug Induced Liver Disease Study Group

Phase

Observational

Started

2023-05-01

Last updated

2025-05-04

Condition(s) studied

Liver InjuryLiver Injury, Drug-Induced

Study summary

This is an open-enrollment, retrospective, observational study without interventions. Its primary objective is to understand 1) incidence of liver injury among all the hospitalized patient from participating centers after the administration of immune checkpoint inhibitors or molecularly targeted agents; 2) epidemiologic and clinical characteristics of liver injury, including suspected medications, clinical types, histological characteristics, severity, treatment and outcomes.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Age ≥ 18 years * Abnormality of liver biochemistry after the administration of any molecularly targeted agent or immune checkpoint inhibitor Exclusion Criteria: * Missing major baseline or clinical data * Prior liver loco-regional therapy or surgery

Primary outcome measure(s)

Change in ALT (alanine aminotransferase) — on day 10
Absolute change

Trial sites (1)

Facility	City	Region	Status
Renji Hospital, Shanghai Jiao Tong University School of Medicine	Shanghai	Shanghai Municipality

More Drug Induced Liver Disease Study Group trials in China

A Prospective Cohort Study on Drug-induced Liver Injury in China（DILI-P） Recruiting

Other trials for the same condition

Protective Mechanisms of Phycocyanin in Partial Hepatectomy-Associated Liver Injury Recruiting

A Prospective Study of ¹⁸F-DFA PET Imaging for the Assessment of Liver Injury Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06670391 on ClinicalTrials.gov ↗ ← All trials in China